Drug List


Drug Name

Ocrevus (Ocrelizumab)

Manufactured By

Genentech, Inc.

Drug Savings

Nationwide Prescription Connection (NPC) is an experienced advocacy service that helps connect patients to manufacturer provided free and discount programs. We can help the uninsured, under insured, those in the Medicare gap also known as the "doughnut hole", or even those needing help with expensive co-pays.  Our web site makes it easy for you to enter the medications you are taking, along with some basic patient information, and then finds the program that is right for you.

NPC's mission is your health. We recognize your need for help when you are applying for discount programs for your prescription medications. We consist of friendly and experienced advocates that not only know how these free and discount programs work, but are ready to help. We are available to take your call and answer any questions you may have as you search for the right program to fit your needs. We can also explain any supporting material you may need to provide as you apply for these programs. If for any reason you are denied, we also are experienced in the best appeals process with a high success rate.

Treats Disease/Condition


A prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis.

How To Use

Ocrevus is administered by intravenous infusion every six months. The first dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions.

Side Effects

May cause serious side effects, including: -- Risk of cancers (malignancies) including breast cancer. Patients should follow their healthcare provider’s recommendations about standard screening guidelines for breast cancer. Most common side effects include infusion reactions and infections. These are not all the possible side effects. Patients should call their doctor for medical advice about side effects. Side effects may also be reported to the FDA at 1-800-FDA-1088.

Drug Interactions

The concomitant use of Ocrevus and other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids, is expected to increase the risk of immunosuppression. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with Ocrevus.

In Case of Overdose

In Case of Missed Dose

If a planned infusion of Ocrevus is missed, administer Ocrevus as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered. Doses of Ocrevus must be separated by at least 5 months


Store Ocrevus vials at 2°C–8°C (36°F–46°F) in the outer carton to protect from light. Do not freeze or shake.